​

Karyopharm Therapeutics Ownership | Who Owns Karyopharm Therapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

Karyopharm Therapeutics Ownership Summary

Karyopharm Therapeutics is owned by 8.68% institutional investors, 5.81% insiders, and 85.52% retail investors. T. rowe price investment management is the largest institutional shareholder, holding 8.13% of KPTI shares. T. Rowe Price Small-Cap Value is the top mutual fund, with 4.68% of its assets in Karyopharm Therapeutics shares.

KPTI Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockKaryopharm Therapeutics8.68%5.81%85.52%
SectorHealthcare Stocks 231.98%10.74%-142.72%
IndustryBiotech Stocks 381.47%10.55%-292.02%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
T. rowe price investment management700.99K8.13%$4.58M
Vanguard group559.62K6.46%$4.12M
Soleus capital management440.00K5.08%$3.24M
Adage capital partners gp421.32K4.89%$2.76M
Blackrock4.17M3.61%$3.62M
Blackrock funding, inc. /de247.56K2.86%$1.82M
Geode capital management187.73K2.17%$1.38M
Catalio capital management, lp142.98K1.66%$935.12K
Avidity partners management lp134.57K1.56%$880.06K
Marshall wace, llp128.45K1.49%$840.07K

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Birchview capital, lp419.83K0.23%$283.93K
Avidity partners management lp134.57K0.20%$880.06K
Catalio capital management, lp142.98K0.17%$935.12K
Soleus capital management440.00K0.12%$3.24M
Silverback asset management40.00K0.03%$261.60K
Ikarian capital27.26K0.02%$178.26K
Adar1 capital management25.00K0.02%$163.50K
C worldwide group100.00K0.01%$736.00K
Xtx topco14.40K0.00%$94.19K
Bridgeway capital management34.87K0.00%$228.07K

Top Buyers

HolderShares% AssetsChange
Soleus capital management440.00K0.12%440.00K
Susquehanna group, llp664.14K0.00%361.60K
Vanguard group559.62K0.00%151.40K
Alyeska investment group144.51K0.00%144.51K
Bank of america corp /de/298.69K-140.77K

Top Sellers

HolderShares% AssetsChange
Blackrock4.17M0.00%-5.28M
Exome asset management---2.00M
Opaleye management---1.43M
Deutsche bank ag\---1.27M
Kennedy capital management---1.20M

New Positions

HolderShares% AssetsChangeValue
Soleus capital management440.00K0.12%440.00K$3.24M
Connor, clark & lunn investment management57.21K0.00%57.21K$421.08K
Jane street group35.53K-35.53K$261.52K
Adar1 capital management25.00K0.02%25.00K$163.50K
Acadian asset management3.73K-3.73K$27.00K

Sold Out

HolderChange
Pittenger & anderson-3.00
Zurcher kantonalbank (zurich cantonalbank)-6.00
Farther finance advisors-13.00
Nelson, van denburg & campbell wealth management group-22.00
Bruce g. allen investments-22.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 202512-79.31%752,172-74.49%80.74%5-72.22%--100.00%
Sep 30, 202518-62.50%552,924-86.33%60.29%5-79.17%3-50.00%
Jun 30, 2025524.00%4,384,528-15.32%50281.78%27575.00%7-83.33%
Mar 31, 202551-45.74%5,312,129-91.28%40.17%4-88.89%4386.96%
Dec 31, 202492-4.17%60,468,4381.78%482.14%3413.33%24-22.58%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
T. Rowe Price Small-Cap Value858.96K4.68%-36.88K
T. Rowe Price U.S. SC Value Eq Tr-D585.32K3.19%319.93K
Vanguard Total Stock Mkt Idx Inv509.13K2.78%263.40K
Vanguard US Total Market Shares ETF3.42M2.71%-1.00
Vanguard Explorer Inv133.88K1.55%-
Vanguard Institutional Extnd Mkt Idx Tr193.82K1.06%-
AlphaCentric LifeSci Healthcare I1.13M0.90%-
AlphaCentric Life Sciences & Hlthcare I1.13M0.89%-
Kennedy Micro Cap1.03M0.81%-22.77K
T. Rowe Price U.S. SC Value Eq Tr-Z50.09K0.60%50.09K

Recent Insider Transactions

DateNameRoleActivityValue
Mar 02, 2026Mano Michael EVP, CLO&SecretarySell$33.18K
Mar 02, 2026Cheng Sohanya Roshan EVP & Chief Commercial OfficerSell$43.32K
Mar 02, 2026Rangwala Reshma EVP & Chief Medical OfficerSell$47.67K
Mar 02, 2026Paulson Richard A. President and CEOSell$116.31K
Mar 02, 2026Poulton Stuart EVP, Chief Development OfficerSell$48.00K

Insider Transactions Trends

DateBuySell
2026 Q1-9
2025 Q4-1
2025 Q3-9
2025 Q2-3
2025 Q1-4

KPTI Ownership FAQ

Who Owns Karyopharm Therapeutics?

Karyopharm Therapeutics shareholders are primarily institutional investors at 8.68%, followed by 5.81% insiders and 85.51% retail investors. The average institutional ownership in Karyopharm Therapeutics's industry, Biotech Stocks , is 381.47%, which Karyopharm Therapeutics falls below.

Who owns the most shares of Karyopharm Therapeutics?

Karyopharm Therapeutics’s largest shareholders are T. rowe price investment management (700.99K shares, 8.13%), Vanguard group (559.62K shares, 6.46%), and Soleus capital management (440K shares, 5.08%). Together, they hold 19.66% of Karyopharm Therapeutics’s total shares outstanding.

Does Blackrock own Karyopharm Therapeutics?

Yes, BlackRock owns 3.61% of Karyopharm Therapeutics, totaling 4.17M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 3.62M$. In the last quarter, BlackRock decreased its holdings by -5.278M shares, a -55.86% change.

Who is Karyopharm Therapeutics’s biggest shareholder by percentage of total assets invested?

Birchview capital, lp is Karyopharm Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.23% of its assets in 419.83K Karyopharm Therapeutics shares, valued at 283.93K$.

Who is the top mutual fund holder of Karyopharm Therapeutics shares?

T. Rowe Price Small-Cap Value is the top mutual fund holder of Karyopharm Therapeutics shares, with 4.68% of its total shares outstanding invested in 858.96K Karyopharm Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools